



# PreadyTake OATP1B3 - Drug-Transporter Interactions Experimental Data

Uptake kinetics of Valsartan, a reference compound of the OATP1B3 transporter. Assays were performed after exposing **PreadyTake OATP1B3** to the shipping medium during a 4-day period and a subsequent 72- hr recovery in fresh culture medium. *These data are the result of 3 independent experiments.*


● HEK-MOCK ● HEK-OATP1B3 ● NET UPTAKE




**Figure 1.** OATP1B3-mediated Valsartan internalization.



**Figure 2.** Valsartan uptake (batch-to-batch variation). *These data are the result of three independent experiments.*



**Figure 3.** OATP1B3 inhibition by Cyclosporin A. Measurement of Valsartan internalization after incubating HEK293 cells in the absence/presence of increasing concentrations of Cyclosporin A.




**Figure 4.** Cyclosporin A inhibition (batch-to-batch variation). *These data are the result of three independent experiments.*


## Quality Controls

A fluorescence-based approach is used to rapidly evaluate **PreadyTake OATP1B3** functionality. Assays were performed after **PreadyTake OATP1B3** was exposed for 4 days to the shipping medium and a subsequent 72-hr culture in fresh medium.

● HEK-MOCK ● HEK-OATP1B3 ● NET UPTAKE




**Figure 5.** OATP1B3-mediated sodium fluorescein internalization. *These data are the result of three independent experiments.*



**Figure 6.** Sodium fluorescein uptake (batch to batch variation). *These data are the result of three independent experiments.*

● 0.5% DMSO ● 1% DMSO ● 2% DMSO



**Figure 7.** Effect of DMSO on OATP1B3 functionality. *These data refer to a single experiment in triplicates.*

OATP1B3 regulatory requirements are detailed in the 2020 FDA and 2012 EMA Drug Interaction Guidelines.